Compare AU
Compare IXJ vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Global Healthcare ETF (IXJ) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IXJ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 260 | 65 |
Median incremental investment | $1,000.00 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,860.32 | $1,955.77 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
IXJ | DRUG | |
|---|---|---|
Strategy | IXJ.AX was created on 2001-11-13 by iShares. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of global biotechnology, healthcare, medical equipment and pharmaceuticals companies and may include large-, mid- or smallcapitalisation stocks | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Eli Lilly and Company (8.25 %) UnitedHealth Group Incorporated (5.81 %) Johnson & Johnson (4.72 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (99.98 %) Communication Services (0.02 %) | Other (76.17 %) Communication Services (33.53 %) Health Care (23.66 %) |
Top 3 countries | United States (99.97 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.46 % | 0.57 % |
Key Summary
IXJ | DRUG | |
|---|---|---|
Issuer | iShares | BetaShares |
Tracking index | S&P Global 1200 Healthcare Sector Index - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.46 % | 0.57 % |
Price | $132.88 | $7.61 |
Size | $1.298 billion | $171.463 million |
10Y return | 91.35 % | N/A |
Annual distribution yield (5Y) | 1.26 % | 1.89 % |
Market | ASX | ASX |
First listed date | 11/03/2009 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IXJ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 260 | 65 |
Median incremental investment | $1,000.00 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,860.32 | $1,955.77 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
IXJ | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IXJ | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |